image credit- Cytiva
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the US-based Danaher Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers.
The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments. It follows five acquisitions made by the companies so far this year.
Cytiva and Pall Corporation’s capacity expansion will increase the manufacture of key products used to make biologic medicines.
The companies are investing $600+ million in chromatography resins; $400+ million in cell culture media; $300+ million in single-use technologies; and $200+ million for continuing expansion work in Cytiva and Pall Corporation’s sites across China and the rest of the Asia-Pacific region, Europe, and the US.
Overall, the companies are planning to hire 2000 people over the next two years to support growth. This is additional to the 2000 new associates hired by Cytiva and Pall Corporation over the last year.
Funds are being allocated to accelerate capacity expansion plans already underway at 13 Pall Corporation and Cytiva sites making biotechnology products for COVID-19 and other critical programs.
